Preoperative serum CA 72.4 as prognostic factor of recurrence and death, especially at TNM stage II, for colorectal cancer

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Ayude, Daniel ^a,b   Rodríguez Berrocal, Francisco J ^a   Ayude, José ^a   Blanco Prieto, Sonia ^a   Vázquez Iglesias, Lorena ^a   Vázquez Cedeira, Marta ^c   Páez De La Cadena, María ^a  

^a UNIVERSITY OF VIGO   (Spain)

^b Department of Biological Production ^*  (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

CA 72.4; CEA; Colorectal cancer; Prognosis; Survival

Indexed keywords

CA 72-4 ANTIGEN; CARCINOEMBRYONIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLON RESECTION; COLORECTAL CANCER; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; SURVIVAL RATE; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; COLORECTAL NEOPLASMS; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREOPERATIVE PERIOD; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887277945     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-543     Document Type: Article

References (40)

1. American Cancer Society Cancer Facts & Figures 2011-13, p 4 2011, Atlanta: American Cancer Society, American Cancer Society.
2. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781. 10.1016/j.ejca.2009.12.014, 20116997.
3. Xu F, Wang F, Di M, Huang Q, Wang M, Hu H, Jin Y, Dong J, Lai M. Classification based on the combination of molecular and pathologic predictors is superior to molecular classification on prognosis in colorectal carcinoma. Clin Cancer Res 2007, 13:5082-5088. 10.1158/1078-0432.CCR-07-0597, 17785561.
4. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009, 58:90-96. 10.1136/gut.2008.155473, 2679586, 18832519.
5. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, Maringe C, Nur U, Tracey E, Coory M, Hatcher J, McGahan CE, Turner D, Marrett L, Gjerstorff ML, Johannesen TB, Adolfsson J, Lambe M, Lawrence G, Meechan D, Morris EJ, Middleton R, Steward J, Richards MA. ICBP Module 1 Working Group: Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data. Lancet 2011, 377:127-138. 10.1016/S0140-6736(10)62231-3, 3018568, 21183212.
6. Lang K, Korn JR, Lee DW, Lines LM, Earle CC, Menzin J. Factors associated with improved survival among older colorectal cancer patients in the US: a population-based analysis. BMC Cancer 2009, 9:227. 10.1186/1471-2407-9-227, 2717120, 19594933.
7. Greene FL, Sobin LH. The staging of cancer: a retrospective and prospective appraisal. CA Cancer J Clin 2008, 58:180-190. 10.3322/CA.2008.0001, 18460593.
8. Sobin C, Wittikind C. TNM classification of malignant tumors 2010, London: Wiley and Sons Inc. New York, 7.
9. Gangadhar T, Schilsky RL. Medscape: Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol 2010, 7:318-325. 10.1038/nrclinonc.2010.62, 20440283.
10. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004, 96:1420-1425. 10.1093/jnci/djh275, 15467030.
11. Saltz LB. Adjuvant therapy for colon cancer. Surg Oncol Clin N Am 2010, 19:819-827. 10.1016/j.soc.2010.07.005, 20883956.
12. André T, Afchain P, Barrier A, Blanchard P, Larsen AK, Tournigand C, Louvet C, de Gramont A. Current status of adjuvant therapy for colon cancer. Gastrointest Cancer Res 2007, 1:90-97. 2632821, 19262714.
13. O'Connell MJ. Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in. J Clin Oncol 2009, 27:3082-3084. 10.1200/JCO.2009.22.2919, 19451420.
14. Marshall JL. Risk assessment in Stage II colorectal cancer. Oncology (Williston Park) 2010, 24(1 Suppl 1):9-13.
15. Guadagni F, Roselli M, Cosimelli M, Ferroni P, Spila A, Cavaliere F, Casaldi V, Wappner G, Abbolito MR, Greiner JW, et al. CA 72-4 serum marker-A new tool in the management of carcinoma patients. Cancer invest 1995, 13:227-238. 10.3109/07357909509011692, 7874576.
16. Reiter W, Stieber P, Reuter C, Nagel D, Cramer C, Pahl H, Fateh-Moghadam A. Prognostic value of preoperative serum levels of CEA, CA 19-9 and CA 72-4 in gastric carcinoma. Anticancer Res 1997, 17:2903-2906.
17. Marelli D, Pinto E, De S, Farnetani M, Garosi L, Roviello F. Clinical Utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg 2001, 181:16-19. 10.1016/S0002-9610(00)00549-3, 11248169.
18. Aloe S, D'Alessandro R, Spila A, Ferroni P, Basili S, Palmirotta R, Carlini M, Graziano F, Mancini R, Mariotti S, Cosimelli M, Roselli M, Guadagni F. Prognostic value of serum and tumor tissue CA 72-4 content in gastric cancer. Int J Biol Markers 2003, 18:21-27.
19. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986, 104:66-73. 10.7326/0003-4819-104-1-66, 3510056.
20. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Dis Colon Rectum 1994, 37:272-277. 10.1007/BF02048166, 8137675.
21. Carpelan-Holmström M, Hanglund C, Lundin J, Alfthan H, Stenman UH, Roberts PJ. Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polpeptide antigen in colorectal cancer. Br J Cancer 1996, 74:925-929. 10.1038/bjc.1996.458, 2074725, 8826859.
22. Hermanek P, Sobin LH. UICC TNM Clasification of malignant tumours: Colon & Rectum. 4th ed, 2nd revision 1992, 52-56. London: Springer.
23. Takagawa T, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, Osada S, Ichikawa Y, Shimada H. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Sug Oncol 2008, 15:3433-3439.
24. Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Järvinen HJ, Haglund C. Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 2002, 101:545-548. 10.1002/ijc.90009, 12237895.
25. Fernández-Rodríguez J, Ayude D, Páez De La Cadena M, Martínez-Zorzano VS, De Carlos A, Caride-Castro A, De Castro G, Rodríguez-Berrocal FJ. Alpha-L-fucosidase enzyme in the prediction of colorectal cancer patients at high risk of tumor recurrence. Cancer Detec Prev 2000, 24:143-149.
26. Ayude D, Páez De La Cadena M, Martínez-Zorzano VS, Fernáncez-Briera A, Rodríguez-Berrocal FJ. Preoperative serum alpha-L-fucosidase activity as prognostic marker in colorectal cancer. Oncology 2003, 64:36-45. 10.1159/000066521, 12457030.
27. Feijoo-Carnero C, Rodríguez-Berrocal FJ, Paez De La Cadena M, Ayude D, De Carlos A, Martínez-Zorzano VS. Clinical significance of preoperative serum sialic acid levels in colorectal cancer: Utility in the detection of patients at high risk of tumor recurrence. Int J Biol Markers 2004, 19:38-45.
28. Desch CE, Benson AB, Somerfield MR, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Pfister DG, Virgo KS, Petrelli NJ. American Society of Clinical Oncology: Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005, 23:8512-8519. 10.1200/JCO.2005.04.0063, 16260687.
29. Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C, Topolcan O. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007, 43:1348-1360. 10.1016/j.ejca.2007.03.021, 17512720.
30. Lindmark G, Kressner U, Bergström R, Glimelius B. Limited clinical significance of the serum tumour marker CA 72-4 in colorectal cancer. Anticancer Res 1996, 16:895-898.
31. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005, 23:609-618.
32. Lanza G, Gafa R, Santini A, Maestri I, Guerzoni L, Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006, 24:2359-2367. 10.1200/JCO.2005.03.2433, 16710035.
33. Funaioli C, Pinto C, Mutri V, Di Fabio F, Ceccarelli C, Martoni AA. Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value?. Clin Colorectal Cancer 2006, 6:38-45. 10.3816/CCC.2006.n.019, 16796790.
34. Zlobec I, Minoo P, Baumhoer D, Baker K, Terracciano L, Jass JR, Lugli A. Multimarker phenotype predicts adverse survival in patients with lymph node-negative colorectal cancer. Cancer 2008, 112:495-502. 10.1002/cncr.23208, 18076013.
35. Zlobec I, Baker K, Terracciano LM, Lugli A. RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis. Clin Cancer Res 2008, 14:3798-3806. 10.1158/1078-0432.CCR-07-5103, 18559599.
36. Uen YH, Lin SR, Wu DC, Su YC, Wu JY, Cheng TL, Chi CW, Wang JY. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection. Ann Surg 2007, 246:1040-1046. 10.1097/SLA.0b013e318142d918, 18043108.
37. Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S, Biasco G. Gene expression profiling in colorectal cancer using microarray technologies: results and perspectives. Cancer Treat Rev 2009, 35:201-209. 10.1016/j.ctrv.2008.10.006, 19081199.
38. Garman KS, Acharya CR, Edelman E, Grade M, Gaedcke J, Sud S, Barry W, Diehl AM, Provenzale D, Ginsburg GS, Ghadimi BM, Ried T, Nevins JR, Mukherjee S, Hsu D, Potti A. A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A 2008, 105:19432-19437. 10.1073/pnas.0806674105, 2592987, 19050079.
39. Thorsteinsson M, Jess P. The clinical significance of circulating tumor cells in non-metastatic colorectal cancer A review. Eur J Surg Oncol 2011, 37:459-465. 10.1016/j.ejso.2011.01.025, 21324632.
40. Kerr D, Gray R, Quirke P, et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study [abstract 4000]. J Clin Oncol 2009, 27(suppl):15s.